Biotech RadarJobs updated

COMPANY

Affinia Therapeutics

HQ: Waltham, MA source · affiniatx.com ↗

Clinical Phase 2

Keywords: gene therapy AAV Dilated Cardiomyopathy BAG3 Mutation Associated Dilated Cardiomyopathy AFTX-201

Location: Waltham, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

1Trials (company is sponsor)

Timeline

  1. Trial start Phase 1/Phase 2: An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM) source ↗
  2. Raise Private equity round — Series C: amount not published, announced Oct 7, 2025. Source: company's own press page. source ↗
  3. Partnership Partnership / licensing announced Jun 3, 2025. Source: company's own press page. source ↗
  4. Partnership Partnership / licensing announced Nov 13, 2024. Source: company's own press page. source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: amount not published. Last 2 years.

Clinical trials (lead sponsor) 1

RecordTitlePhaseStatusStartPrimary completion
NCT07426419An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM)Phase 1/Phase 2Recruiting2026-092028-12 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback